Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
25.8 EUR | -.--% | -4.44% | -10.42% |
21/05 | Genmab A/S Reaffirms Financial Guidance for 2024 | CI |
21/05 | Genmab A/S completed the acquisition of ProfoundBio, Inc. | CI |
Sales 2024 * | 19.8B 2.88B 2.65B 240B | Sales 2025 * | 23.62B 3.43B 3.16B 286B | Capitalization | 125B 18.17B 16.73B 1,515B |
---|---|---|---|---|---|
Net income 2024 * | 4.67B 679M 626M 56.68B | Net income 2025 * | 6.61B 962M 886M 80.22B | EV / Sales 2024 * | 5 x |
Net cash position 2024 * | 25.9B 3.77B 3.47B 314B | Net cash position 2025 * | 32.35B 4.7B 4.33B 392B | EV / Sales 2025 * | 3.92 x |
P/E ratio 2024 * |
28.5
x | P/E ratio 2025 * |
20.5
x | Employees | 2,286 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.51% |
Latest transcript on Genmab A/S
1 week | -4.44% | ||
1 month | -0.77% | ||
6 months | -9.15% | ||
Current year | -10.42% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 63 | 01/99/01 | |
Anthony Pagano
DFI | Director of Finance/CFO | 46 | 01/07/01 |
Anthony Mancini
COO | Chief Operating Officer | 53 | 23/20/23 |
Members of the board | Title | Age | Since |
---|---|---|---|
Deirdre Connelly
CHM | Chairman | 63 | 01/17/01 |
Director/Board Member | 73 | 01/03/01 | |
Rolf K. Hoffmann
BRD | Director/Board Member | 64 | 01/16/01 |
Date | Price | Change |
---|---|---|
31/24/31 | 25.8 | -.--% |
30/24/30 | 25.8 | -.--% |
29/24/29 | 25.8 | -2.27% |
28/24/28 | 26.4 | +2.33% |
27/24/27 | 25.8 | -4.44% |
Delayed Quote Börse Stuttgart, May 31, 2024 at 06:57 pm IST
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+11.91% | 118B | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B | |
+77.64% | 8.87B |
- Stock Market
- Equities
- GMAB Stock
- GE91 Stock